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Objective To evaluate the long-term validity and safety of pure oats in the treatment of children with celiac disease.
Study design This noninferiority clinical trial used a double-blind, placebo-controlled, crossover design ex-
tended over a 15 months period of time. There were 306 children with a biopsy-proven diagnosis of celiac disease
on a gluten-free diet for ≥2 years were randomly assigned to eat specifically prepared gluten-free food containing
an age-dependent amount (15-40 g) of either placebo or purified nonreactive varieties of oats for 2 consecutive
6-month periods separated by washout standard gluten-free diet for 3 months. Clinical (body mass index, Gastro-
intestinal Symptoms Rating Scale score), serologic (IgA antitransglutaminase antibodies, and IgA anti-avenin an-
tibodies) and intestinal permeability data were measured at baseline, and after 6, 9, and 15 months. Direct treatment
effect was evaluated by a nonparametric approach using medians (95% CI) as summary statistic.
Results After the exclusion of 129 patients who dropped out, the cohort included 177 children (79 in the oats–
placebo and 98 in the placebo–oats group; median, 0.004; 95% CI, −0.0002 to 0.0089). Direct treatment effect
was not statistically significant for clinical, serologic, and intestinal permeability variables (body mass index: median,
−0.5; 95% CI, −0.12 to 0.00; Gastrointestinal Symptoms Rating Scale score: median, 0; 95% CI, −2.5 to 0.00; IgA
antitransglutaminase antibodies: median, −0.02; 95% CI, −0.25 to 0.23; IgA anti-avenin antibodies: median, −0.0002;
95% CI, −0.0007 to 0.0003; intestinal permeability test: median, 0.004; 95% CI, −0.0002 to 0.0089).
Conclusions Pure nonreactive oat products are a safe dietary choice in the treatment of children with celiac
disease. (J Pediatr 2017;■■:■■-■■).
Trial Registration ClinicalTrials.gov NCT00808301
C eliac disease is a systemic immune-mediated disorder caused by the ingestion of gluten-containing grains in geneti-cally susceptible persons.1 The only available treatment for celiac disease is the gluten-free diet (GFD), which consistsin the dietary exclusion of grains containing gluten (ie, wheat, rye, barley,
triticale, semolina or durum wheat, spelt, and kamut).2 The need to exclude oats
from the GFD has been long a matter of debate and it remains controversial.3 Early
feeding experiments suggested that oats, like wheat and barley, were toxic for celiacs.4,5
However, it is now recognized that the oat products used in early studies may have
been heavily contaminated with other gluten-containing cereals.3 A large body of
evidence has so far suggested that the consumption of pure oats is safe in the vast
majority of patients with celiac disease.6-25 Nonetheless, some concerns persist re-
garding the tolerance and the safety of oats for all patients with celiac disease. The
purity of oat products cannot always be guaranteed, and the contamination of oats
with other gluten-containing cereals during harvesting and milling is known to
occur.26,27 A small subset of patients with celiac disease experience more abdomi-
nal symptoms while consuming an oat-containing diet as compared with a con-
ventional GFD28,29; some oats varieties show toxicity in vitro, suggesting that there
AB Group A→B
BA Group B→A
AGA Antigliadin deamidated antibodies
ELISA Enzyme-linked immunosorbent assay
GFD Gluten-free diet
GSRS Gastrointestinal Symptom Rating Scale
IPT Intestinal permeability test
L/M Ratio of lactulose percent to mannitol percent
TGA2 Antitransglutaminase antibodies
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are differences between oat varieties in relation to their safety
or toxicity for people with celiac disease.30 Finally, 3 patients
have been described so far who developed villous atrophy after
oat challenge.28,30
Previous studies were limited by (1) small sample sizes, (2)
short follow-up periods, (3) the absence of any detail about
the variety of oat used, or (4) not being ruled out that oat prod-
ucts were free of contamination by other gluten-containing
cereals. To the best of our knowledge, there has been only 1
double-blind, randomized, placebo-controlled clinical trial.13
Therefore, we aimed to evaluate the clinical, serologic, and
mucosal safety of uncontaminated and nonreactive varieties
of oats in the treatment of Italian children with celiac disease
in a large, long-term, randomized, double-blind, crossover,
placebo-controlled, noninferiority, multicenter clinical trial.
Methods
This noninferiority intervention trial (ClinicalTrials.gov:
NCT00808301) used a crossover design. The study protocol
has been described previously.31 All children (range, 4-14 years
of age) with a biopsy-proven diagnosis of celiac disease, on a
GFD for ≥2 years, were recruited at 8 pediatric gastroenter-
ology centers in Italy (Ancona, Bari, Catania, Monza, Palermo,
Roma, and Cava de’ Tirreni) between 2008 and 2012. Pa-
tients who (1) had other chronic conditions (including type
1 diabetes or inflammatory bowel disease) or (2) did not adhere
to the GFD (as demonstrated by elevation of serologic markers
at enrollment) were excluded. The random allocation se-
quence was generated by 2 investigators with no clinical in-
volvement in the trial, the enrollment and the assignment of
participants to interventions were performed in each center
by the principal investigators). All investigators, staff, and par-
ticipants were blinded to the allocation. On the basis of a strati-
fied randomization, children were assigned to 1 of 2 groups:
those in group A→B (herein described as AB) received 6
months of a GFD plus A products, then 3 months of washout
with a standard GFD, and eventually 6 months of GFD plus
B products, and those in group B→A (herein described as BA)
received 6 months of a GFD plus B products, 3 months of
washout with a standard GFD, and finally 6 months of GFD
plus A products. A and B products were gluten-free flour, pasta,
biscuits, cakes, and crisp toasts containing either purified oats
or placebo, respectively; they were provided to the patients free
of charge by a company that is leader in the production of
gluten-free products in Italy (Heinz Italia s.p.a, Italy), and were
identical in form and appearance. Products contained the oats
varieties “Irina” and “Potenza”Avena sativa, which never pre-
sented the immune reactivity associated with toxic prola-
mins in vitro.32 Oats were specially grown, milled, and packaged
so as not to become contaminated with wheat, rye, or barley.
Gluten contamination was double checked by the
RIDASCREEN ELISA (R-Biopharm AG, Darmstadt, Germany).
The required oat intake (calculated as 1 g/kg/day) was 15 g/
day in children aged 3-6 years, 25 g/day in children between
7 and 10 years of age, and 40 g/day in children aged 11-16 years.
Clinical, serologic, and mucosal parameters were mea-
sured at baseline (B1), at the end of the first 6-month period
(T6), at the end of the 3-month washout (B2) and at the end
of the second 6-month intervention period (T15). At each time
point, the daily intake of oat was assessed by means of a 3-day
food diary and symptoms and/or side effects related to the in-
gestion of the products under investigation were promptly
recorded.
Clinical Assessment
At every timepoint, all children were interviewed to recall gas-
trointestinal symptoms and the following data were col-
lected: (i) body mass index, (ii) the 15-item Gastrointestinal
Symptom Rating Scale (GSRS) score to assess severity and fre-
quency of symptoms,33 and (iii) questions to assess other vari-
ables that may have affected study results (ie, infections, life
events). The following symptoms were investigated specifi-
cally: epigastric burning and/or pain, abdominal pain, acid re-
gurgitation, heartburn, sucking sensation in the epigastrium,
nausea, vomiting, bloating, abdominal distension, eructa-
tion, increased flatus, disorders of defecation (decreased/
increased passage of stools, consistency of stools [loose/
hard], urgency, feeling of incomplete evacuation), lack of
appetite, halitosis, and taste disturbance. The questionnaire was
completed by a parent–child team approach. In detail, the symp-
toms were scored on a 4-point scale by the child together with
a family member after a simple explanation of the questions
by physicians: mild (not interfering with daily activities), mod-
erate (slightly interfering with daily activities), severe (inter-
fering with daily activities), and very severe (continuous). Stool
consistency was graded from hard (0) to watery (4). Severe side
effects related to the ingested products were recorded at each
timepoint of follow-up.
All serum samples were kept frozen at −20°C until analysis
in a single laboratory at Buccheri-La Ferla Hospital (Palermo,
Italy). Serum antitransglutaminase antibodies (TGA2) were
measured by means of a commercial enzyme-linked
immunosorbent assay (ELISA; Menarini Diagnostics, Winnersh,
UK). More than 20 arbitrary units indicated a positive result.
Deamidated gliadin antibodies (AGA IgA and IgG) were mea-
sured by means of ELISA with the use of a commercial kit
(Menarini Diagnostics), and >15 arbitrary units indicated a
positive result. IgA anti-avenin antibodies were measured by
ELISA, developed and validated by one of our team members,
and >0.1 arbitrary units indicated a positive result.
The mucosal integrity was evaluated by a noninvasive pro-
cedure, the intestinal permeability test (IPT), as described
previously.32,34 Briefly, after an overnight fast and bladder emp-
tying, an oral solution containing 5 g of lactulose and 2 g of
mannitol was administered. Urine was collected over the fol-
lowing 5 hours. An aliquot was preserved at −20°C with sodium
azide. Urinary excretion of each sugar was assessed using a high
performance anion exchange chromatography (Dionex DX-
500). The ratio of recovered to ingested sugar was reported as
the ratio of lactulose percent to mannitol percent (L/M). Ac-
cording to our own reference values, a urinary L/M ratio
of >0.08 was considered abnormal (data not published). All
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IPTs were performed in the Laboratory of the Department of
Pediatrics, Università Politecnica delle Marche (Ancona, Italy).
We aimed to evaluate the noninferiority of a GFD plus pure
nonreactive oats as compared with a standard GFD in main-
taining remission of celiac disease in children. The primary re-
sponse variable was IPT, as a marker of mucosal integrity. A
difference in direct treatment effect between the 2 diets of 0.01
as maximum was considered not significant clinically. Sec-
ondary outcome measures were difference in direct treatment
effect between the 2 diets in clinical and serologic variables.
The Institutional Review Board of the Coordinating Center
(Università Politecnica delle Marche, Ancona, Italy) and of each
participating center approved this study protocol. Written, in-
formed consent was obtained from the parents or guardians
of the children.
Statistical Analyses
The sample size for a noninferiority assessment was esti-
mated using IPT as the primary response variable and calcu-
lating a 95% CI for the mean difference of the primary response
in the 2 diets. One hundred seventy-seven patients ensured to
estimate a 95% CI considering a clinical difference between
the 2 diets (D) of 0.01 as maximum, a standard deviation of
0.025, a level of significance of 2.5%, and a power of 80%.
Because data were not distributed normally, a nonparamet-
ric approach was used for all the statistical analysis. Subjects’
general characteristics were summarized using descriptive sta-
tistics: median, first and third quartiles for quantitative vari-
ables, and absolute and percent frequencies for qualitative
variable. Comparisons between the 2 groups were performed
by means of Wilcoxon rank-sum test and c2 test, respectively.
For descriptive purposes, absolute variations in clinical and
anthropometric variables between T6 and B1 and T15 and B2,
respectively, in the first and second periods of treatment were
calculated and graphically represented by boxplots. The 95%
CI for median values were calculated and comparisons between
diet groups in each treatment period were performed using
the Wilcoxon rank-sum test. A positive variation indicated an
increase in the variable that was considered statistically sig-
nificant when the 95% CI did not contain zero value.
A first-order carryover effect, direct-by-period interac-
tion, (q, l), and direct treatment effect (t) were evaluated using
a nonparametric approach using medians as summary statistic.35
The CIs for each effect (q, l, t) were estimated using a prob-
ability of 0.90 for the first 2 and of 0.95 for the third. A prob-
ability of 0.05 was chosen to assess the statistical significance;
the R program was used for statistical analysis.
Results
Unmasking of the blind showed that products A contained oats
and products B placebo. The flow diagram of the study is shown
in (Figure 1; available at www.jpeds.com). Of 306 random-
ized children, 129 withdrew from the study. Overall, there was
a significantly higher frequency of withdrawals in the group
AB as compared with group BA; in detail, the percentage of
dropouts at T3 was not different between the 2 groups; however,
at T6 there was a significantly higher percentage of dropouts
in group AB (ie, at the end of the A period), that remained
significantly higher at B2, and at T12 and T15 (ie, during the B
period).Table I (available at www.jpeds.com) shows the reasons
for withdrawal. There was no difference between the 2 groups
in the number of children withdrawn for the presence of symp-
toms related to the protocol; the most common reasons for
giving up in both groups were inability to ingest the assigned
amount of intervention food or to attend the follow-up visits.
All dropouts were TGA2 and IPT negative at the time they with-
drew from the study.
After exclusion of the 129 dropouts, the cohort included 177
children (79 in group A and 98 in group B). There were 124
girls (70%), and the median age of the cohort at study entry
was 9.1 years of age (IQR, 6.9-11.6). Table III shows the
patient’s main anthropometric and clinical characteristics at
baseline. No differences were found between the 2 groups.
Ninety-seven percent of patients achieved the required oats
intake.
The absolute differences observed in the first and second treat-
ment period in the 2 groups in clinical, serologic, and IPT pa-
rameters are shown inTable II (available at www.jpeds.co) and
in Figures 2-4. A significant increase in body mass index was
observed in the 2 treatment periods for both diet sequences,
probably related to the high intake of commercial gluten-free
products required for the protocol. A significant decrease was
found in GRSR score in group BA in the first period; AGA IgA
significantly increased in the second period in the AB group.
No differences were found between the 2 groups in the 2 treat-
ment periods for all the variables of interest.
Table III shows the results of crossover analysis. The dif-
ferences in treatment carryover at the time of the second base-
line measurement (first-order carryover [q]) and differences
in treatment carryover at the time of the second treatment mea-
surement (second-order carryover or direct by period inter-
action [l]) were not statistically significant for all the variables,
because all the 90% CIs included a zero value. A direct treat-
ment effect (t) was found not statistically significant for all
clinical, serologic, and mucosal variables studied. The upper
limit of 95% CI of IPT direct treatment effect was found lower
than the highest difference considered clinically relevant
(D = 0.01).
The number of children that tested positive at serologic and
IPT assessment at T6 and T15 of follow-up according to treat-
ment groups is shown inTable IV (available at www.jpeds.com).
There was no difference in the percentage of children testing
positive for AGA, TGA2, anti-avenin, or IPT test between the
2 groups in the 2 treatment periods, suggesting that the oc-
casional positivity was not related to the type of intervention
food, but to poor adherence to the GFD. No severe side effects
related to the ingestion of the products under investigation were
recorded in the 2 groups during the 2 treatment periods.
Discussion
In this double-blind, placebo-controlled study, the long-
term introduction of pure nonreactive oats-based products in
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children with celiac disease treated with a GFD had no del-
eterious effect at the clinical, serologic, or mucosal levels. The
present finding is consistent with previous studies showing that
medium to high amounts of gluten-uncontaminated oats can
be ingested safely by patients with celiac disease.6-25 Early short-
term reports showing controversial results on oats toxicity were
based on the record of gastrointestinal symptoms; however,
they did not rule out that the oat products used in these studies
were free of contamination with other cereals.4,5 In 1995, Finnish
investigators first compared the effect of 50-70 g/day of oats
with placebo in 92 adults with celiac disease on a GFD at di-
agnosis or in follow-up. They found no difference in clinical
and laboratory outcomes and, more important, there was no
sign of histologic damage after 12 months of an oat-containing
GFD.6 There were no signs of toxicity of oats in the same group
of adult patients with celiac disease participating in a 5-year
follow-up study, indicating the long-term safety of oats as part
of a celiac diet.7 These data have been replicated in other clini-
cal trials both in adults and children affected with celiac
disease,6-23 and supported by in vitro immunologic results in
A
B
Figure 2. A, B, Absolute variation (D) in median body mass
index (BMI) (A) and GSRS (B) in the 2 treatment periods ac-
cording to treatment groups.
A
B
Figure 3. A, B, Absolute variation (D) in median TGA2 (A) and
anti-avenin (B) results in the 2 treatment periods according to
treatment groups.
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organ culture systems,24,25 as summarized in systematic
reviews.3,36
The putative nontoxic nature of oats for patients with celiac
disease as compared with “toxic cereals” is mirrored by the taxo-
nomic classification of cereals. Oats, rye, barley, and wheat are
members of a subfamily of grains, the Pooidae. This subfam-
ily is further divided into the triticae, to which wheat, rye and
barley belong, and the avenae, whose only member is oats. These
divisions are based on the structure of the grains’ storage pro-
teins. The prolamin fraction contains gliadin in wheat. Oats
prolamin includes avenin, a protein that, although having some
sequence homology with gliadin, is distinct from it and from
the prolamins found in rye and barley.3 Recent studies suggest
that some oat varieties may show a degree of residual toxic-
ity in vitro, for the presence of a peptide with a high content
of proline and glutamine, suggesting that there are differ-
ences between oat varieties in relation to their safety or
toxicity for people with celiac disease.30,32 In our study, we used
the naked oats A sativa “Irina” and “Potenza,” which never pre-
sented the significant immunoreactivity associated with toxic
prolamins in previous in vitro studies.32
Oats avenin, although structurally different, is also present
as only 5%-15% of total oat protein, as opposed to the pro-
lamin content of the triticae subgroup, which is as high as 50%.
It has been argued that, in large quantities, avenin may still be
toxic, suggesting the concept of an exposure threshold, which
needs to be exceeded before symptoms occur. If this is the case,
a greater amount of oats may need to be consumed before a
toxic threshold is reached.3 In the present study, a moderate
to high amount of daily oats (1 g/kg up to 40 g/day for older
children) seemed not to be harmful.
The strengths of the present study are the study design (ie,
a placebo-controlled intervention with a crossover), the large
sample size, the long duration of the study (15 months), and
the type of products containing selected nonreactive variet-
ies of oats. We provided commercially available gluten-free
products, routinely consumed by patients with celiac disease,
with added oats, that were identical in form and appearance
to gluten-free products containing placebo. Only 1 study has
been performed so far giving gluten-free products with and
without oats in a double-blind fashion and, interestingly, it
showed results comparable with our findings.13
Based on a literature review of the studies including the his-
tologic assessment,6,8-10,13-15,28 only 1 patient developed villous
atrophy after consuming oats28; the same patient was in-
cluded in another uncontrolled study by the same investiga-
tors in which 2 more patients developed villous atrophy.30 We
are aware that the lack of the small intestinal mucosa histol-
ogy is a weakness of our study; however, we decided to avoid
the histologic assessment because performing repeated follow-
up small intestinal biopsies was deemed unethical in chil-
dren. Nonetheless, we evaluated the mucosal integrity by a
noninvasive procedure, that is, the IPT, that is a sensitive tool
for both triage of active celiac disease, as well as for monitor-
ing patients with celiac disease on a GFD.37 In patients with
active celiac disease, a sugar “paradox” pathway is usually ob-
served: the amount of urinary recovered mannitol is de-
creased owing to the reduced absorptive surface of the small
intestine (villous atrophy), and urinary recovered lactulose is
Figure 4. Absolute variation (D) in median IPT results in the
2 treatment periods according to treatment groups.
Table III. Results from the crossover analysis*
q l t
Median (1-a/2 % CI)† First-order carryover effect Direct-by-period interaction Direct treatment effect
BMI 0.084 (−0.05; 0.20) 0.05 (−0.15; 0.20) −0.5 (−0.12; 0)
BMI class 0.50 (−1.0; 1.50) 0.50 (−1.0; 2.0) −0.25 (−1.0; 0.25)
GRSR score 0 (0; 0) 0 (−0.5; 0) 0 (−2.5; 0)
AGA IgA 0.29 (−0.35; 0.90) 0.14 (−0.70; 1.05) −0.15 (−0.50; 0.25)
AGA IgG 0.29 (−0.35; 0.90) 0.15 (−0.70; 1.05) −0.15 (−0.50; 0.25)
TGA2 0.4 (−0.05; 0.95) 0.30 (−0.25; 0.80) −0.02 (−0.25; 0.23)
IPT 0.001 (−0.01; 0.01) −0.003 (−0.014; 0.007) 0.004 (−0.0002; 0.0089)
Anti-avenin 0.0005 (−0.0005; 0.0014) −0.0005 (−0.0019; 0.0005) −0.0002 (−0.0007; 0.0003)
BMI, Body mass index.
*First-order carryover effect, direct-by-period interaction, direct treatment effect according to the sequences AB, BA. Differences are 15 vs 9 months' measurements.
†The 90% CI for q and l; 95% CI for t.
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increased because of damage to the tight junctions and con-
sequent widening of paracellular spaces. For these reasons, an
increased disaccharide/monosaccharide excretion ratio is the
usual finding associated with celiac disease damage of the small
intestinal mucosa. In adults with celiac disease, the IPT has been
shown to be more sensitive than serologic methods in moni-
toring patients during follow-up and detecting minimal changes
related to gluten ingestion.38,39 In the present study, we did not
find significant changes in the urinary L/M ratio either in group
AB or BA, and the upper limit of 95% CI of IPT direct treat-
ment effect was found to be lower than the greatest differ-
ence considered clinically relevant, showing that a GFD
including oats was not inferior to a standard GFD in main-
taining mucosal remission, as assessed by the IPT test, in chil-
dren with celiac disease under treatment.
During our prolonged follow-up, we also tested the humoral
response to transglutaminase-2, which is highly sensitive for
active celiac disease. We found no difference in the percent-
age of children testing positive at TGA2 between the 2 groups,
confirming the safety of prolonged oats ingestion.
According to the current literature, some patients with
celiac disease experience gastrointestinal symptoms more
often on an oats-containing diet than with a traditional
GFD.7,8 By using a cross-over study design, we excluded the
role of oats in inducing symptoms and/or withdrawal. Indeed,
we found a higher frequency of withdrawals in the group AB
during the first treatment period, which included oats, as
compared with group BA during diet B (ie, placebo); however,
after the crossover, we still found a higher frequency of
withdrawals in the group AB during diet B (ie, placebo) as
compared with group BA, which was consuming diet A (ie,
oats), therefore excluding that the withdrawal was caused by
the oats. Moreover, there was no difference between the 2
groups with regard to the number of children withdrawn for
the presence of symptoms at all time points of follow-up.
The major reason for withdrawal was the long duration of
the study, with several visits of follow-up that had an unfa-
vorable impact on the family daily life, leading to an inability
to complete the study.
Finally, the addition of nonreactive, noncontaminated oats
had no significant impact on the GSRS score, a validated ques-
tionnaire for the assessment of gastrointestinal complaints.
Indeed, we found no differences between the 2 groups in the
2 treatment periods regarding absolute variations in the GSRS
score, and the direct treatment effect on GSRS score was also
not statistically significant.
In contrast, a Norwegian research group demonstrated that
some patients with celiac disease may have gastrointestinal
symptoms while ingesting an oats-containing diet because they
are intolerant to oats owing to the presence of avenin-reactive
T cells in the small bowel mucosa.22 In our study, there was
no difference between the 2 groups in direct treatment effect
as regard the anti-avenin antibodies titers, suggesting that oats
do not produce a significant humoral response in patients with
celiac disease.
The inclusion of oats in a GFD would have several poten-
tial benefits for patients with celiac disease. First, oats are a good
source of fiber, especially beta-glucan, which is important in
human nutrition for its outstanding functional properties, such
as the attenuation of postprandial plasma glucose and insulin
responses, high transport of bile acids toward lower parts of
the intestinal tract, and high excretion of bile acids, thereby
lowering serum cholesterol levels.40 Oats are also a good source
of B complex vitamins, iron, and thiamine. They have a higher
satiety value than other gluten-free cereals,40 and increase the
palatability and variety of the GFD, thus improving compli-
ance and reducing the risk of accumulating possible contami-
nants (ie, arsenic or mycotoxins).
In conclusion, based on this and previous studies, selected
uncontaminated and nonreactive varieties of oats can be safely
included in the GFD used to treat children affected with celiac
disease. As there are several potential benefits of including oats
in the GFD and there will be a possible market demand for
oat products among patients with celiac disease; celiac soci-
eties and the industry should make an effort to promote the
production and sale of safe oat products free of gluten
contamination. ■
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(Group AB = 154; Group BA = 152)
Drop-out = n: 129
Group AB: n= 75 (58%) Symptoms: 10
Lack of adherence: 48
Other reasons: 17
Group BA: n= 54 (42%) Symptoms: 5






At time of drop-out





Figure 1. Flow diagram of the study.
Table I. Reasons for withdrawal at all time points of
follow-up according to treatment groups
Times Groups, n (%) P
3 months (T3) AB (n = 43) BA (n = 29)
Symptoms related to the protocol 9 (20.9) 5 (17.2) .174
Inability to attend the follow-up visit 15 (34.9) 14 (48.3)
Inability to follow the diet 13 (30.2) 3 (10.3)
Other reasons (parental problems, etc) 6 (14) 7 (24.1)
6 months (T6) (n = 13) (n = 6)
Symptoms related to the protocol 0 (0) 0 (0) 1.000
Inability to attend the follow-up visit 11 (84.6) 5 (83.3)
Inability to follow the diet 1 (7.7) 0 (0)
Other reasons (parental problems, etc) 1 (7.7) 1 (16.7)
9 months (B2) (n = 10) (n = 5)
Symptoms related to the protocol 1 (10) 0 (0) .476
Inability to attend the follow-up visit 3 (30) 4 (80)
Inability to follow the diet 1 (10) 0 (0)
Other reasons (parental problems, etc) 5 (50) 1 (20)
12 months (T12) (n = 6) (n = 12)
Symptoms related to the protocol 0 (0) 0 (0) 1.000
Inability to attend the follow-up visit 2 (33.3) 4 (33.3)
Inability to follow the diet 2 (33.3) 3 (25)
Other reasons (parental problems, etc) 2 (33.3) 5 (41.7)
15 months (T15) (n = 3) (n = 2)
Other reasons (parental problems, etc) 3 2
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Table II. Absolute variation in the 2 treatment periods according to treatment groups
First period (T6-B1) Second period (T15-B2)
n AB n BA P n AB n BA P
Weight
Median (95% CI) 102 2 (1.69 to 2.31)* 114 2 (1.67 to 2.33)* .765 88 2 (1.59 to 2.41)* 90 1.7 (1.33 to 2.07)* .279
First to third quartiles 1 to 3 1.0 to 3.2 1.00 to 3.45 0.8 to 3.0
BMI
Median (95% CI) 79 0.4 (0.19 to 0.61)* 98 0.4 (0.22 to 0.58)* .785 79 0.2 (0.01 to 0.39)* 98 0.3 (0.11 to 0.49)* .506
First to third quartiles −0.3 to 0.9 −0.1 to 1.0 −0.25 to 0.80 −0.3 to 0.9
BMI class
Median (95% CI) 79 1 (−0.87 to 2.87) 98 0.5 (−0.46 to 1.46) .877 79 0 (−1.6 to 1.6) 98 0 (−1.12 to 1.12) .413
First to third quartiles −4.5 to 6.0 −2 to 4 −5 to 4 −3 to 4
GRSR score
Median (95% CI) 79 0 (−0.36 to 0.36) 98 −0.5 (−0.82 to −0.18)* .314 78 0 (−0.18 to 0.18) 97 0 (−0.16 to 0.16) .183
First to third quartiles −2 to 0 −2 to 0 −1 to 0 0 to 1
AGA IgA
Median (95% CI) 76 0.15 (−0.48 to 0.78) 92 0.3 (−0.35 to 0.95) .984 62 0.8 (0.17 to 1.43)* 85 −0.1 (−0.99 to 0.79) .512
First to third quartiles −1.26 to 2.20 −1.68 to 2.30 −1.05 to 2.10 −2.5 to 2.7
AGA IgG
Median (95% CI) 77 0.5 (−0.27 to 1.27) 92 −0.2 (−1.12 to 0.72) .166 62 0.3 (−0.62 to 1.22) 84 −0.39 (−0.87 to 0.09) .095
First to third quartiles −2.0 to 2.3 −3.45 to 2.15 −1.9 to 2.7 −1.85 to 0.92
TTG IgA
Median (95% CI) 76 −0.04 (−0.54 to 0.46) 93 0.1 (−0.47 to 0.67) .103 72 0.2 (−0.32 to 0.72) 90 0.45 (−0.23 to 1.13) .613
First to third quartiles −1.70 to 1.09 −1.10 to 2.40 −1.05 to 1.75 −1.50 to 2.60
IPT
Median (95% CI) 75 0 (−0.0091 to 0.0091) 89 0 (−0.0101 to 0.0121) .64 67 0 (−0.01 to 0.02) 77 −0.01 (−0.02 to 0) .059
First to third quartiles −0.0255 to 0.0245 −0.029 to 0.037 −0.03 to 0.04 −0.04 to 0.01
Anti-avenin IgA
Median (95% CI) 74 0 (−0.0015 to 0.0015) 93 −0.001 (−0.002 to 0) .247 73 0.001 (−0.0005 to 0.0025) 93 0.001 (0 to 0.002) .468
First to third quartiles −0.004 to 0.004 −0.004 to 0.002 −0.002 to 0.006 −0.002 to 0.004
BMI, Body mass index.
*Indicates a significant variation of the variable of interest in each group between T6 and B1 and between T15 and B2, respectively (95% CI did not contain zero value); P values refer to Wilcoxon
rank-sum tests for the comparisons between the 2 groups.
Table IV. Clinical and laboratory evaluation (expressed
as negative = normal or positive = abnormal) at T6 and
T15 according to treatment groups
T6 T15
AB BA P AB BA P
GSRS score 79 98 78 97
Negative (=0) 39 (49.4) 57 (58.2) .31 47 (60.3) 56 (57.7) .855
Positive (>0) 40 (50.6) 41 (41.8) 31 (39.7) 41 (42.3)
Aga IgA 78 93 69 92
≤20 74 (94.9) 84 (90.3) .407 65 (94.2) 84 (91.3) .697
>20 4 (5.1) 9 (9.7) 4 (5.8) 8 (8.7)
Aga Ig G 78 93 69 92
≤20 72 (92.3) 82 (88.2) .520 65 (94.2) 84 (91.3) .697
>20 6 (7.7) 11 (11.8) 4 (5.8) 8 (8.7)
TGA2 78 95 76 94
≤20 78 (100) 91 (95.8) .128* 75 (98.7) 90 (95.7) .382*
>20 0 (0) 4 (4.2) 1 (1.3) 4 (4.3)
IPT 76 90 69 84
≤0.08 55 (72.4) 60 (66.7) .532 48 (69.6) 67 (79.8) .206
>0.08 21 (27.6) 30 (33.3) 21 (30.4) 17 (20.2)
Anti-avenin 75 94 74 96
≤0.1 71 (94.7) 92 (97.9) .409* 71 (95.9) 92 (95.8) 1
>0.1 4 (5.3) 2 (2.1) 3 (4.1) 4 (4.2)
c2 test.
*Fisher exact test.
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